1. 1702 Patients enrolled in the accelerating medicines partnership (AMP) RA/SLE network with isolated renal disease report minimal quality of life impairment on PROMIS-29 compared to patients with extrarenal symptoms. (14th December 2022) Authors: Carlucci, Philip; Li, Jessica; Gold, Heather T; Deonaraine, Kristina; Fava, Andrea; Buyon, Jill; James, Judith A; Putterman, Chaim; Rao, Deepak; Diamond, Betty; Fine, Derek; Monroy-Trujillo, Jose; Haag, Kristin; Apruzzese, William; Michael Belmont, H; Connery, Sean; Payan-Schober, Fernanda; Furie... Journal: Lupus science & medicine Issue: Volume 9(2022)Supplement 3 Page Start: A102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. (25th February 2022) Authors: Carlucci, Philip M; Li, Jessica; Fava, Andrea; Deonaraine, Kristina K; Wofsy, David; James, Judith A; Putterman, Chaim; Diamond, Betty; Davidson, Anne; Fine, Derek M; Monroy-Trujillo, Jose; Atta, Mohamed G; DeJager, Wade; Guthridge, Joel M; Haag, Kristin; Rao, Deepak A; Brenner, Michael B; Ledere... Journal: Rheumatology Issue: Volume 61:Number 11(2022) Page Start: 4335 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗